0
Original Research: INTERVENTIONAL PULMONOLOGY |

Transbronchoscopic Pulmonary Emphysema Treatment*: 1-Month to 24-Month Endoscopic Follow-up

Hugo G. de Oliveira, MD, PhD; Amarilio V. Macedo-Neto, MD, PhD; Angela B. John, MD; Sandra Jungblut, MD; João Carlos Prolla, MD, PhD; Sérgio S. Menna-Barreto, MD, PhD; Elaine A. F. Fortis, MD
Author and Funding Information

*From the Departments of Thoracic Surgery (Drs. de Oliveira and Macedo-Neto), Pulmonology (Drs. John and Menna-Barreto), Radiology (Dr. Jungblut), Pathology (Dr. Prolla), and Anesthesiology (Dr. Fortis), Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

Correspondence to: Hugo G. de Oliveira, MD, PhD, Department of Thoracic Surgery, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos 2350, Sala 2050 MI CEP, 90035-004 Porto Alegre, RS, Brazil; e-mail: hugo@oliveira.com



Chest. 2006;130(1):190-199. doi:10.1378/chest.130.1.190
Text Size: A A A
Published online

Objective: Describe the results of a 1- to 24-month follow-up of individuals undergoing transbronchoscopic placement of one-way valves.

Design: Longitudinal, noncomparative study.

Setting: University hospital.

Patients: Nineteen heterogeneous emphysema patients.

Measurements and results: Pulmonary function testing, imaging examination, and videobronchoscopy were performed at 1, 3, 6, 12, and 24 months after the insertion of one-way valves. Mean age was 67.63 ± 8.71 years, mean body mass index (BMI) was 24.02 ± 2.65, and mean exposure to smoking was 65.32 ± 27.46 pack-years (± SD). Baseline BODE index (BMI, degree of airflow obstruction and dyspnea, exercise capacity as measured by the 6-min walk test [6MWT]) was 7 to 10 in 10 patients (estimated 4-year mortality, 80%) and 5 to 6 in 9 patients (estimated 4-year mortality, 40%). Sixty-four valves were inserted. There was no procedure-related mortality. Nonsustained atelectasis was observed within 48 h in 2 of 12 patients with right upper lobe occlusion. Fifty-six bronchoscopic examinations were performed in 24 months. Granulomas not requiring treatment were the main complication. Mucus clogging the valve, mainly at 1 month, was easily cleaned. Eighteen patients completed the 1- and 3-month follow-ups, 14 patients completed the 6-month follow-up, 11 patients completed the 12-month follow-up, and 5 patients completed the 24-month follow-up. Improvement was observed in the 6MWT after 1 month (p = 0.028) and in the BODE index at 3 months (p = 0.002). FEV1 or FVC improvement ≥ 12% or ≥ 150 mL was observed, respectively, in 4 of 18 patients and 8 of 18 patients at 1 month, 4 of 18 patients and 7 of 18 patients at 3 months, and in 3 of 14 patients and 5 of 14 patients at 6 months. After 24 months, one of five patients and three of five patients, respectively, retained an FEV1 and FVC change ≥ 12% or ≥ 150 mL. Significant improvement (decrease ≥ 4%) in the St. George Respiratory Questionnaire was observed at 3 months and 6 months in three of four domains.

Conclusion: Endobronchial valves are safe, but the criteria to measure improvement and to select patients should be refined. Atelectasis should be reconsidered as primary treatment goal.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543